Have we reached the limits for the treatment of diabetic nephropathy?

Expert Opinion on Investigational Drugs

Volumn 23, Issue 4, 2014, Pages 511-522

  Hajhosseiny, Reza ^b   Khavandi, Kaivan ^b   Jivraj, Naheed ^c   Mashayekhi, Soudeh ^d   Goldsmith, David J ^e   Malik, Rayaz A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bardoxolone; Chronic kidney disease; Diabetic nephropathy; Pyridoxamine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATRASENTAN; BARDOXOLONE METHYL; CONNECTIVE TISSUE GROWTH FACTOR; HEPARANASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PYRIDOXAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VITAMIN D DERIVATIVE;

CANCER GROWTH; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; EXERCISE; GLYCATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; VALIDITY;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; OLEANOLIC ACID; PYRIDOXAMINE; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84896110752     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.892580     Document Type: Review

References (113)

1. Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J kidney Dis 2009;53(3 Suppl 3):S17-26
2. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J kidney Dis 2007;50(2):169-80 (Pubitemid 47095094)
3. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80
4. System USRD. International Comparisons. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2013
5. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007;27(2):195-207 (Pubitemid 46550314)
6. Fioretto P, Mauer M, Carraro A, et al. Renal structural changes in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997;10(9 Pt 2):184S-8S
7. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;39(12):1569-76 (Pubitemid 26397369)
8. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S424-37 (Pubitemid 32577594)
9. Ohsawa M, Fujioka T, Ogasawara K, et al. High risks of all-cause and cardiovascular deaths in apparently healthy middle-aged people with preserved glomerular filtration rate and albuminuria: A prospective cohort study. Int J Cardiol 2013;170(2):167-72
10. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382(9888):260-72
11. Jha V, Wang AY, Wang H. The impact of CKD identification in large countries: the burden of illness. Nephrol Dial Transpl 2012;27(Suppl 3):332-8
12. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14
13. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47 (Pubitemid 350074801)
14. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4(8):444-52
15. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 2010;3(2):101-8
16. Mott JD, Khalifah RG, Nagase H, et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997;52(5):1302-12 (Pubitemid 27496059)
17. Silbiger S, Crowley S, Shan Z, et al. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int 1993;43(4):853-64 (Pubitemid 23105219)
18. Yang CW, Vlassara H, Peten EP, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994;91(20):9436-40 (Pubitemid 24297929)
19. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91(24):11704-8 (Pubitemid 24356413)
20. Yamagishi S, Takeuchi M, Makita Z. Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib Nephrol 2001;134:30-5
21. Pedchenko VK, Chetyrkin SV, Chuang P, et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005;54(10):2952-60 (Pubitemid 41401092)
22. Cai W, He JC, Zhu L, et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006;103(37):13801-6 (Pubitemid 44413988)
23. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end productinduced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277(23):20309-15 (Pubitemid 34967325)
24. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108(2):261-8 (Pubitemid 32656250)
25. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162(4):1123-37 (Pubitemid 36350658)
26. Heizmann CW. The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Mol Nutr Food Res 2007;51(9):1116-19
27. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010;59(1):249-55
28. Kanesaki Y, Suzuki D, Uehara G, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005;45(2):288-94 (Pubitemid 40431054)
29. Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol 2012;32(4):385-93
30. Baelde HJ, Eikmans M, Lappin DW, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71(7):637-45 (Pubitemid 46494557)
31. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51(10):3090-4
32. de Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12(5):993-1000 (Pubitemid 32378340)
33. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331(19):1286-92 (Pubitemid 24333194)
34. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990;86(2):453-62 (Pubitemid 20271877)
35. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995;44(10):1139-46
36. Yamamoto T, Nakamura T, Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90(5):1814-18 (Pubitemid 23069947)
37. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66(6):2137-47 (Pubitemid 41115277)
38. Zimanyi MA, Denton KM, Forbes JM, et al. A developmental nephron deficit in rats is associated with increased susceptibility to a secondary renal injury due to advanced glycation end-products. Diabetologia 2006;49(4):801-10 (Pubitemid 43357555)
39. Tanimoto M, Gohda T, Kaneko S, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007;56(2):160-7 (Pubitemid 46074060)
40. Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17(12):1762-4
41. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42(5):579-88 (Pubitemid 29196009)
42. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11(1):25-38 (Pubitemid 30020423)
43. Roestenberg P, van Nieuwenhoven FA, Wieten L, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27(5):1164-70 (Pubitemid 38579784)
44. Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17(9):2484-94 (Pubitemid 44300964)
45. Twigg SM, Cao Z, SV MC, et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002;143(12):4907-15 (Pubitemid 35397630)
46. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008;82(Suppl 1):S42-5
47. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62 (Pubitemid 23335891)
48. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
49. Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007;30(4):995-6 (Pubitemid 46556600)
50. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28(11):2686-90 (Pubitemid 43951160)
51. Budhiraja S, Singh J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam Clin Pharmacol 2008;22(3):231-40 (Pubitemid 351712894)
52. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res 2012;111(8):1091-106
53. Dugan LL, You YH, Ali SS, et al. AMPK dysregulation promotes diabetesrelated reduction of superoxide and mitochondrial function. J Clin Invest 2013;123(11):4888-99
54. Chen JL, Francis J. Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy. J Am Soc Nephrol 2012;23(1):6-8
55. Furukawa M, Gohda T, Tanimoto M, Tomino Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. ScientificWorldJournal 2013;2013:928197
56. Onuigbo M. Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: a New classification scheme for renoprotective agents. Nephron Extra 2013;3(1):36-49
57. Fried LF, Emanuele N, Zhang JH, et al. Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892-903
58. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57(2):601-6 (Pubitemid 30430652)
59. Liao J, Kobayashi M, Kanamuru Y, et al. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol 2003;16(6):841-9 (Pubitemid 38714227)
60. Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19(12):3012-20 (Pubitemid 40057622)
61. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51(11):3274-82 (Pubitemid 35246974)
62. Yamagishi S, Takeuchi M, Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)- injected rats. Drugs Exp Clin Res 2005;31(2):45-51 (Pubitemid 350056455)
63. Sebekova K, Gazdikova K, Syrova D, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003;17(4):265-70 (Pubitemid 36592018)
64. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006;74(2):201-3 (Pubitemid 44764907)
65. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
66. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8
67. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118(8):577-81 (Pubitemid 23102690)
68. Moon JY, Tanimoto M, Gohda T, et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol 2011;300(6):F1271-82
69. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367(23):2204-13
70. Onuigbo MA. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? Int J Clin Pract 2010;64(10):1341-6
71. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010;55(5):928-40
72. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257(2):251-8 (Pubitemid 29301430)
73. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62(15):1671-81 (Pubitemid 41176049)
74. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275(28):21177-84 (Pubitemid 30481811)
75. Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002;277(5):3397-403 (Pubitemid 34953208)
76. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocindiabetic rat. Kidney Int 2002;61(3):939-50 (Pubitemid 34175462)
77. Zheng F, Zeng YJ, Plati AR, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70(3):507-14 (Pubitemid 44141577)
78. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27(6):605-14 (Pubitemid 350014947)
79. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24(1):32-40 (Pubitemid 38250484)
80. Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):131-6.
81. Schwartz MM, Lewis EJ, Leonard-Martin T, et al. pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998;13(10):2547-52 (Pubitemid 28445867)
82. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011;33(5):469-76
83. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365(4):327-36
84. Li W, Khor TO, Xu C, et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008;76(11):1485-9
85. Dinkova-Kostova AT, Liby KT, Stephenson KK, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 2005;102(12):4584-9 (Pubitemid 40397155)
86. Levonen AL, Landar A, Ramachandran A, et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J 2004;378(Pt 2):373-82 (Pubitemid 38367228)
87. Honda T, Rounds BV, Gribble GW, et al. Design and synthesis of 2-cyano- 3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8(19):2711-14 (Pubitemid 28496657)
88. Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NFkappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006;281(47):35764-9 (Pubitemid 46041307)
89. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NFkappa B signaling pathway. Proc Natl Acad Sci USA 2000;97(9):4844-9 (Pubitemid 30238645)
90. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010;298(3):F662-71
91. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 2006;168(6):1960-74 (Pubitemid 43825316)
92. Hong DS, Kurzrock R, Supko JG, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2012;18(12):3396-406
93. Saha PK, Reddy VT, Konopleva M, et al. The triterpenoid 2-cyano- 3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 2010;285(52):40581-92
94. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369(26):2492-503
95. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-8 (Pubitemid 44967731)
96. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73(2):163-71
97. Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008;105(41):15896-901
98. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18(6):1796-806 (Pubitemid 46870316)
99. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17(12):3382-93 (Pubitemid 44865281)
100. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110(2):229-38 (Pubitemid 34787360)
101. Yuan W, Pan W, Kong J, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007;282(41):29821-30 (Pubitemid 350035242)
102. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011;22(9):1603-9
103. Inoue K, Matsui I, Hamano T, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. Lab Invest 2012;92(12):1686-97
104. de Borst MH, Hajhosseiny R, Tamez H, et al. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 2013;24(11):1863-71
105. Masola V, Onisto M, Zaza G, et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelialmesenchymal transition. J Transl Med 2012;10:213
106. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23(1):123-30
107. Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87(2):161-9 (Pubitemid 32215829)
108. Andress DL, Coll B, Pritchett Y, et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012;91(13-14):739-42
109. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21(3):527-35
110. McClellan WM, Plantinga LC. A public health perspective on CKD and obesity. Nephrol Dial Transplant 2013;28(Suppl 4):iv37-42
111. Boor P, Celec P, Behuliak M, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58(11):1669-77
112. Ishikawa Y, Gohda T, Tanimoto M, et al. Effect of exercise on kidney function, oxidative stress, and inflammation in type 2 diabetic KK-A(y) mice. Exp Diabetes Res 2012;2012:702948
113. Palmer-Smith S, Rosser LG, Tull J, et al. X-linked lissencephaly with ambiguous genitalia - a case presentation. J Med Genet 2011;48:S58-8